Fortress Biotech announces an exclusive license agreement for FB-607 for IBS-D treatment
FBIO•Fortress Biotech announced an exclusive license agreement for FB-607 to treat irritable bowel syndrome with diarrhea (IBS-D).
1. License agreement
Fortress Biotech announced an exclusive license agreement for FB-607 for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
